Shilpa Medicare receives EU GMP approval from Germany
Pharma company Shilpa Medicare today said it has received European Union GMP approval from Germany for two of its manufacturing sites for production of cancer drugs.
The first site located at Deosugur Industrial Area will produce Temozolomide used in the treatment of aggressive brain tumour and Melanoma, a type of skin cancer, the company said in a statement.
The second approval is for the plant located at Raichur Industrial Growth Centre, which will manufacture Capecitabine used in the treatment of breast cancer and colorectal cancers.
The approvals come after the sites were inspected by German Health Authorities in February this year, it said.
The scrips of the company were trading at Rs 357 per share at the BSE, up 1.91 per cent at late afternoon trade.